<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEPROBAMATE <img border="0" src="../images/pr.gif"/></span><br/>(me-proe-ba'mate)<br/><span class="topboxtradename">Equanil, </span><span class="topboxtradename">Meprospan, </span><span class="topboxtradename">Miltown<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">carbamate</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span><br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Propanediol carbamate derivative structurally and pharmacologically related to carisoprodol. CNS depressant actions similar
         to those of barbiturates. Acts on multiple sites in CNS and appears to block corticothalamic impulses. No effect on medulla,
         reticular activating system, or autonomic nervous system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antianxiety agent. Hypnotic doses suppress REM sleep.</p>
<h1><a name="uses">Uses</a></h1>
<p>To relieve anxiety and tension of psychoneurotic states and as adjunct in disease states associated with anxiety and tension.
         Also used to promote sleep in anxious, tense patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to meprobamate or related carbamates such as carisoprodol and tybamate; history of acute intermittent
         porphyria; pregnancy (category D), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; convulsive disorders; history of alcoholism or drug abuse; patients with suicidal tendencies.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.21.6 g/d in 34 divided doses (max: 2.4 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 100200 mg b.i.d. or t.i.d.<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400800 mg<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 200 mg 23 times/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 200 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to minimize gastric distress.</li>
<li>Treatment physical dependence by gradual drug withdrawal over 12 wk to prevent onset of withdrawal symptoms.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise specified by manufacturer.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergy or idiosyncratic reactions (itchy, urticarial, or erythematous maculopapular rash; <span class="speceff-life">exfoliative dermatitis</span>, petechiae, purpura, ecchymoses, eosinophilia, peripheral edema, angioneurotic edema, adenopathy, fever, chills, proctitis,
      bronchospasm, oliguria, anuria, <span class="speceff-life">Stevens-Johnson syndrome</span>); <span class="speceff-life">anaphylaxis</span>. <span class="typehead">CNS:</span> <span class="speceff-common">Drowsiness</span> and <span class="speceff-common">ataxia,</span> dizziness, vertigo, slurred speech, headache, weakness, paresthesias, impaired visual accommodation, paradoxic euphoria and
      rage reactions, seizures in epileptics, panic reaction, rapid EEG activity. <span class="typehead">CV:</span> Hypotensive crisis, syncope, palpitation, tachycardia, arrhythmias, transient ECG changes, <span class="speceff-life">circulatory collapse</span> (toxic doses). <span class="typehead">GI:</span> Anorexia, nausea, vomiting, diarrhea. <span class="typehead">Hematologic:</span> <span class="speceff-life">Aplastic anemia</span> (rare): leukopenia, <span class="speceff-life">agranulocytosis, thrombocytopenia</span>, exacerbation of acute intermittent porphyria. <span class="typehead">Respiratory:</span> <span class="speceff-life">Respiratory depression</span>. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Meprobamate may cause falsely high <span class="alt">urinary steroid</span> determinations. <span class="alt">Phentolamine</span> tests may be falsely positive; meprobamate should be withdrawn at least 24 h and preferably 4872 h before the test.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol entacapone,</b> <span class="classification">tricyclic antidepressants</span>, <span class="classification">antipsychotics</span>, <span class="classification">opiates</span>, <span class="classification">sedating antihistamines</span>, <b>pentazocine,</b> <b>tramadol,</b> <span class="classification">maoi</span>s, <span class="classification">sedative-hypnotics</span>, <span class="classification">anixiolytics</span> may potentiate CNS depression. <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Distribution:</span> Uniformly distributed throughout body; crosses placenta. <span class="typehead">Metabolism:</span> Rapidly metabolized in liver. <span class="typehead">Elimination:</span> Renally excreted; excreted in breast milk. <span class="typehead">Half-Life:</span> 1011 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation, if necessary. Older adults and debilitated patients are prone to oversedation and to the hypotensive
            effects, especially during early therapy.
         </li>
<li>Utilize safety precautions for hospitalized patients. Hypnotic doses may cause increased motor activity during sleep.</li>
<li>Consult physician if daytime psychomotor function is impaired. A change in regimen or drug may be indicated.</li>
<li>Withdraw gradually in physically dependent patients to prevent preexisting symptoms or withdrawal reactions within 1248
            h: Vomiting, ataxia, muscle twitching, mental confusion, hallucinations, convulsions, trembling, sleep disturbances, increased
            dreaming, nightmares, insomnia. Symptoms usually subside within 1248 h.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug as prescribed. Psychic or physical dependence may occur with long-term use of high doses.</li>
<li>Be aware that tolerance to alcohol will be lowered.</li>
<li>Make position changes slowly, especially from lying down to upright; dangle legs for a few minutes before standing.</li>
<li>Avoid driving or engaging in hazardous activities until response to drug is known.</li>
<li>Report immediately onset of skin rash, sore throat, fever, bruising, unexplained bleeding.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>